ArticleJournal of pharmaceutical health care and sciences2026
Influence of Helicobacter pylori eradication blister-pack handling on outpatient AWaRe access share: a Japanese community pharmacy-based sensitivity analysis.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHelicobacter pylori (H. pylori) eradication regimens may influence outpatient AWaRe Access share when routine surveillance is based on oral antibacterials classified under the Anatomical Therapeutic Chemical (ATC) code J01. This study evaluated how commercially identifiable H. pylori eradication blister-pack handling affects the reported AWaRe Access share using community pharmacy dispensing data.
methodsWe analyzed monthly outpatient dispensing data for oral antibacterials in ATC J01 from community pharmacies in Nayoro, Japan, from July 2022 to March 2025. AWaRe Access share was primarily compared between an unadjusted series and a pack-adjusted series in which commercially identifiable eradication blister packs were handled using a predefined pack-derived offset. An exploratory extended adjustment also considered probable non-pack eradication regimens. Blister packs were identified by product name. In the pack-adjusted series, pack days of therapy were conservatively converted into a DDD-equivalent offset and subtracted from both the numerator and denominator. The primary outcome was the monthly difference in Access share between the unadjusted and pack-adjusted series (ΔAccess).
resultsAmong 20,129 oral J01 records, commercially identifiable eradication blister packs accounted for a median of 1.13% of monthly records and 0.55% of monthly DOT. The difference between the unadjusted and pack-adjusted series (ΔAccess) was positive in all 33 months, with a median of 0.59% points (pp) (IQR, 0.47-0.83; range, 0.26-1.43). These findings indicate that the handling of commercially identifiable eradication blister packs had a consistent but modest influence on the reported Access share.
conclusionsThe handling of commercially identifiable H. pylori eradication blister packs had a consistent but modest influence on outpatient AWaRe Access share derived from dispensing data. Although the observed difference was modest in this low-Access-share setting, explicit reporting of blister-pack handling may improve transparency, particularly in benchmark-based or close comparative evaluations. Routine AWaRe surveillance should therefore define how commercially identifiable eradication packs are handled, ideally using standardized adjustment or dual reporting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.